Article summary
Law360, London: The UK’s antitrust enforcer on 20 July 2020 resumed probes of allegedly anti-competitive market allocation agreements for two drugs used to treat urinary tract infections and nausea, after the investigations largely stalled this spring amid delays due to the novel coronavirus (COVID-19) pandemic.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial